NASDAQ$RNA

Atrium Therapeutics Inc · Q3 2023 earnings

Q3 2023 earnings ·

Headline financials

Total Revenue

$2.82M

Previous: $2.48M+13.5%
EPS

-$0.71

Previous: -$0.82+13.4%
Capital Expenditures

-$3.37M

Previous: -$1.97M-70.6%
Free Cash Flow

-$55.7M

Previous: -$45.6M-22.3%
Net Income

-$52.4M

Previous: -$43.6M-20.1%
Operating Income

-$58.6M

Previous: -$44.9M-30.5%
Gross Profit

$0.00

Previous: $0.00

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$2.82M

Q3 2023+13.5%vs Q3 2022
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro